thase (NOS)-2, and macrophage migration inhibitory factor (16, 20, 30, 34) , indicating a classical M1-type macrophage phenotype. However, as acute inflammation is replaced by progressive fibrosis, the role of macrophages in chronic kidney disease becomes less clear. Furthermore, there is an increasing awareness of the heterogeneous nature of macrophage responses and how this is determined by their local microenvironment (2, 8) .
Experimental studies of macrophage function in RPGN have focused mainly on models of nephrotoxic serum nephritis (NTN) and lupus nephritis. A variety of strategies to block macrophage infiltration or activation during the development of inflammatory lesions has proven effective in preventing/halting active crescent formation and renal dysfunction, demonstrating that macrophages cause acute renal injury in this setting (5, 9, 11, 12, 15, 22) . In contrast, the role of macrophages in established crescentic disease when predominant inflammatory lesions give way to a progressive fibrotic phase is poorly understood. Thus, it is unclear whether macrophages are a suitable target during the progressive fibrotic phase of RPGN. Studies of macrophages in progressive interstitial fibrosis in the unilateral ureteric obstruction model have produced conflicting results (3, 10, 18, (25) (26) (27) (28) , and these data cannot readily be extrapolated to a model of RPGN.
The aim of the current study was to examine macrophage function during the fibrotic phase of crescentic glomerulonephritis. To achieve this, we used an inhibitor of the macrophage-specific c-fms receptor, termed fms-I (9, 24) , to deplete monocyte/macrophages in the established fibrotic phase of rat crescentic NTN.
MATERIALS AND METHODS
Reagents. Mouse monoclonal antibodies were as follows: CD68 (ED1), T cell receptor (R73), vimentin, endothelium (RECA-1) (Dako, Glostrup, Denmark), and ␣-smooth muscle actin (␣-SMA; Sigma, Castle Hill, NSW, Australia). Polyclonal antibodies were goat anti-collagen IV, rabbit anti-Wilm's tumor antigen 1 (WT-1), and rabbit anti-PDGF-BB (Santa Cruz Biotechnology, Santa Cruz, CA).
4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1- (9, 24) .
Rat NTN. Male Wistar-Kyoto rats (180 -200 g) were obtained from the Animal Resource Centre (Perth, Australia). Groups of eight rats were immunized with 1 mg of sheep IgG in Freund's complete adjuvant followed 5 days later (day 0) by tail vein injection of sheep anti-rat glomerular basement membrane (GBM) serum. Animals were given fms-I (10 or 30 mg/kg twice a day) or vehicle alone (20% hydroxylpropyl-␤-cyclodextrin in H 2O) by oral gavage beginning 14 days after anti-GBM serum injection and continued twice daily until rats were killed on day 35. A group of untreated rats (NoTx) was killed on day 14 to serve as a control for disease severity at the beginning of fms-I treatment. A group of eight normal rats was also analyzed. Overnight urine (22 h) was collected on days 5, 10, 21, 28 , and 35. Animal experimentation was approved by the Monash Medical Centre Animal Ethics Committee and was performed in accordance with the Australian National Health and Medical Research Council guidelines for animal experimentation.
Blood was collected at the time of death. Analysis of serum and urine creatinine used the Jaffe reaction with alkaline picrate. White blood cell counts were performed on a Cell Dyn 3500 Cell Counter (Abbott Laboratories, Abbott Park, IL). Urine protein levels were quantified using a Coomassie (Bradford) Protein Assay Kit (Thermo Fisher Scientific, Rockland, IL).
Histology. Glomerular pathology including the percentage of glomeruli with crescent formation, the size of crescents, crescent type (cellular/fibrocellular/fibrous), and the presence of Bowman's capsule rupture was examined on periodic acid Schiff-stained sections. Each full-sized glomerular cross-section (gcs) within the section (Ͼ50) was viewed under high power (ϫ400) and scored as follows. Glomerular crescents were defined as the presence of two or more layers of cells within Bowman's space. The circumferential size of crescents within Bowman's space was scored as follows: 0, no crescent; the crescent occupying one quadrant (1ϩ), two quadrants (2ϩ), three quadrants (3ϩ), or all 4 quadrants (4ϩ) of Bowman's space. All scoring was performed on blinded slides.
Immunohistochemistry and quantification. Immunoperoxidase staining for R73ϩ T cells and RECA-1ϩ endothelium was performed on cryostat sections. Immunostaining for ED1, ␣-SMA, WT-1, collagen IV, and vimentin was performed on formalin-fixed paraffin sections as previously described (9) . For double staining, paraffin sections were first stained with the ED1 antibody using a peroxidase-based method with development of a brown color using diaminobenzidine. Sections were then microwave treated and then stained for PDGF-BB using an alkaline phosphatase-based method with development of a purple color using the BCIP/NBP substrate (Sigma). Periglomerular myofibroblasts were assessed as the percentage of glomeruli exhibiting multiple continuous layers of ␣-SMAϩ immunostaining. The number of ED1ϩ macrophages, R73ϩ T cells, and WT-1ϩ podocytes per gcs was counted under high power (Ͼ50 gcs per section). The area of glomerular tuft collagen IV deposition was quantified by image analysis. High-power (ϫ400) digital images of glomerular tuft collagen IV staining were analyzed using Image-Pro software (Media Cybernetics) to determine the area of collagen IV staining as a percentage of the total area of the glomerular tuft. Interstitial collagen IV, ␣-SMA, and ED1 staining was quantified by image analysis using fields covering Ͼ90% of the cortex (avoiding glomeruli and vessels) using Image-Pro software. Interstitial R73ϩ T cells were counted in Ͼ20 high-power interstitial fields per section. Vimentin staining of tubular cross-section was assessed in 50 consecutive fields (ϫ250) using: 0, no positive cells; 1ϩ, few (1 or 2) positive tubular cells in the tubule; 2ϩ, more than 2, but less than half of cells stained; 3ϩ, more than half of cells stained in the tubule. The peritubular capillary rarefaction index of peritubular capillary sparseness (0 to 100%) was determined by counting the numbers of squares in 12ϫ16 grids that did not contain RECA-1ϩ peritubular capillary staining in at least 12 consecutive medium-power (ϫ16) fields. The minimum possible capillary rarefaction index is 0 if every square in the grid contains a RECA-1ϩ capillary, while the maximal score is 100 when RECA-1ϩ capillaries are absent from every square in the grid. All scoring was performed on blinded slides.
Real-time RT-PCR. The RiboPure RNA isolation kit (Ambion, Austin, TX) was used to extract RNA from frozen whole kidney samples. Reverse transcription and real-time PCR was performed using Taqman probes together with an 18S or GAPDH internal control as previously described (9, 24) . The IL-2 primers and probes were purchased from Applied Biosystems. The other primer pairs and probes are listed in Table 1 .
Statistics. Data are shown as means Ϯ SD and results were analyzed using parametric ANOVA with post hoc analysis with Bonferroni's posttest for multiple comparisons. Nonparametric data were analyzed by the Kruskal-Wallis ANOVA by ranks using Dunn's posttest for multiple comparisons. All analyses were performed using the software in GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).
RESULTS
Crescentic glomerulonephritis on day 14 of NTN. Rats killed on day 14 after administration of anti-GBM serum showed marked glomerular damage including hypercellularity and hyalinosis, with crescent formation in 50% of glomeruli (Fig. 1, A, B,  E) . Glomerular crescents were predominantly of the fibrocellular type (89.9 Ϯ 9.1%) with a small percentage of cellular crescents (9.9 Ϯ 9.4%), but no fibrous crescents were seen at this time.
Crescents involved one-half of the circumference of the glomerulus and were associated with rupture of Bowman's capsule that was present in ϳ80% of glomeruli (Fig. 1, B, F, G) . Glomerulosclerosis was also evident on day 14 with a significant increase in glomerular collagen IV deposition and ␣-SMAϩ myofibroblast accumulation (Figs. 2, A-D, I, and 3, A, B, E) , and an increase in renal mRNA levels of collagen I, plasminogen activator inhibitor (PAI)-1, and transforming growth factor (TGF)-␤1 (Fig. 4, A-C) . Day 14 NTN also featured tubulointerstitial damage with tubular atrophy, cast formation, and interstitial leukocyte infiltration (Fig.  5, A and B) . Tubulointerstitial damage was also identified by tubular dilation, de novo tubular vimentin expression, marked upregulation of KIM-1 mRNA levels, loss of peritubular capillaries, periglomerular and interstitial ␣-SMAϩ myofibroblast accumulation, and collagen IV deposition (Figs. 2 to 5 ). In addition, heavy proteinuria with podocyte loss and renal dysfunction were established on day 14 (Fig. 6) . These lesions were associated with prominent glomerular and interstitial macrophage infiltration (Fig.  7, A, B, F, G) . Analysis of macrophage-specific markers using real-time PCR of whole kidney RNA showed high mRNA levels of the proinflammatory M1 markers NOS2 and matrix metalloproteinase-12 (MMP-12) and relatively low mRNA levels of M2 alternative activation markers CD163 and CD206 (Fig. 8) , indicating a predominant M1-type macrophage phenotype. In addition, two-color staining identified PDGF-B expression by macrophages, including macrophage giant cells, in the glomerular tuft and in crescents on day 14 NTN (Fig. 7E) . A significant glomerular and interstitial T cell infiltrate was also evident, with increased mRNA levels of IL-12 and IL-17A indicating T cell activation (Fig. 9) .
Fibrotic progression of NTN over days 14 to 35 . No change in the frequency of glomerular crescents was seen over days 14 to 35 in vehicle-treated NTN (Fig. 1, C and E) . Fibrocellular crescents accounted for 95.5 Ϯ 4.1% of total crescents in vehicle-treated rats at day 35 of NTN (P Ͼ 0.05 vs. day 14). However, there was some fibrous progression of crescents over this time; cellular crescents were no longer detected on day 35, and 3.5 Ϯ 4.1% of crescents were of a fibrous type at day 35. There was no change in the size of crescents or in the frequency of Bowman's capsule rupture (Fig. 1, F and G) , but there was a significant increase in collagen IV deposition within the glomerular tuft (Fig. 2, E, F, I ). Tubulointerstitial damage worsened over days 14 to 35 with increased collagen IV deposition, increased interstitial volume, and an increase in tubular dilation and vimetin expression (Figs. 2 and 5) . However, capillary rarefaction and KIM-1 mRNA levels were unchanged between days 14 and 35 (Figs. 4 and 5) . Heavy proteinuria and renal dysfunction continued unabated over days 14 to 35 (Fig. 6 ).
An interesting feature of this progressive fibrotic phase over days 14 to 35 was the Ͼ50% reduction in macrophage accumulation, in both glomerular and interstitial compartments (Fig. 7) and reduced CD68 mRNA levels (Fig. 8A ). This is suggestive of "burn out" of an acute inflammatory lesion, although kidney TNF-␣ mRNA levels remained elevated on day 35 (Fig. 4E) . PCR analysis shows a reduction in expression of M1 markers (NOS2, MMP-12) and an increase in the expression of M2 markers (CD163, CD206) relative to CD68 mRNA levels (Fig. 8) . Finally, the glomerular T cell infiltrate had resolved by day 35, but interstitial T cell infiltration and activation were unaltered (Fig. 9) . 
Effect of fms-I treatment over days 14 to 35 of rat NTN.
Low-and high-dose fms-I treatment was well-tolerated. Both doses of fms-I abrogated glomerular and interstitial macrophage by day 35 NTN (Fig. 7) , in association with a substantial reduction in blood monocyte numbers. There was no difference in blood lymphocyte or neutrophil counts between vehicle-and drug-treated rats on day 35, although high-dose fms-I caused a minor reduction in overall white blood cell counts (Fig. 7) . Fms-I treatment did not affect T cell infiltration or activation (Fig. 9) .
Macrophage depletion using fms-I did not change the number of glomerular crescents compared with the day 14 NoTx group, although there was a minor reduction in glomerular crescent numbers in the high-dose fms-I group on day 35 compared with vehicle-treated day 35 (Fig. 1, D and E) . There was a small, but significant, reduction in crescent size with fms-I treatment on day 35, although the frequency of disruption of Bowman's capsule was unaltered (Fig. 1, F and G) . Treatment with fms-I significantly reduced glomerular and interstitial collagen IV deposition and reduced interstitial volume on day 35 NTN. This was accompanied by a reduction in the percentage of glomeruli with multiple layers of periglomerular ␣-SMAϩ myofibroblasts, although interstitial ␣-SMAϩ myofibroblast accumulation was unchanged (Figs. 2 and 3 ). This re- duction in glomerular and interstitial fibrosis was associated with a reduction in renal mRNA levels of collagen I, PAI-1, and TGF-␤1 (Fig. 4, A-C) , and protection from further interstitial capillary loss (Fig. 5G) . However, fms-I-based macrophage depletion had no effect on other parameters of tubulointerstitial damage, including tubular dilation, tubular vimentin expression, and KIM-1 mRNA levels (Figs. 4 and 5) . Of note, macrophage depletion improved renal function and reduced TNF-␣ mRNA levels on day 35, although proteinuria continued unabated (Figs.  4 and 6) .
DISCUSSION
This study evaluated the role of macrophages in the fibrotic phase of established experimental crescentic glomerulonephritis. This disease model showed a distinct change from inflammatory lesions to chronic fibrotic damage over days 14 to 35. No further crescent formation or disruption of Bowman's capsule occurred after day 14 in the vehicle-treated group, indicating that this is a model of established crescentic disease. Compared with the dramatic pathologic changes seen over the first 14 days of this model, pathologic change over days 14 to 35 was relatively modest, although there was a clear increase in the severity of fibrosis in the glomerular tuft, periglomerular area, and tubulointerstitium. Notably, the aggressive macrophage infiltrate in glomerular and tubulointerstitial compartments seen on day 14 reduced by over 50% during the subsequent period of established crescentic disease. Therefore, this study enables examination of macrophage function in the chronic phase of severe kidney disease and provides a contrast with the prominent proinflammatory and injurious role that macrophages play during the development of crescentic disease during the first 14 days in this model.
Treatment with fms-I induced selective depletion of macrophages in the injured kidney as shown by the lack of effect on circulating lymphocyte and neutrophil numbers and the lack of effect upon interstitial T cell infiltration or T cell activation (IL-2 and IL-17). As previously discussed (9), the mechanisms by which fms-I treatment depleted macrophages in the injured kidney may include reduced blood monocyte numbers, reduced local proliferation, and reduced survival of macrophages within the kidney. Both doses of fms-I resulted in blood monocyte depletion, suggesting that the inability to renew the macrophage infiltrate through recruitment of blood monocytes is likely to be the major mechanism of macrophage depletion in this model of rat NTN.
Macrophage depletion via fms-I treatment over days 14 to 35 improved renal function and provided partial protection against glomerular and tubulointerstitial fibrosis and peritubular capillary rarefaction, demonstrating a significant role for macrophages in the fibrotic phase of NTN despite ongoing proteinuria and the continued presence and activation of T cells. In particular, there was a clear reduction in glomerular collagen deposition and periglomerular ␣-SMAϩ myofibroblast accumulation, with a more minor reduction seen in overall interstitial fibrosis. The results indicate that macrophages are not required to sustain the interstitial ␣-SMAϩ myofibroblast population, but the reduction in mRNA levels of collagen I, PAI-1, and TGF-␤1 argues that macrophages are required to sustain the full fibrotic response. In addition, the observation that macrophages in the glomerulus and in crescents make PDGF-B provides one possible mechanism whereby macrophages can recruit and induce proliferation of periglomerular ␣-SMAϩ myofibroblasts. This macrophage profibrotic function in established disease is consistent with clinical findings that interstitial macrophage numbers correlate with declining renal function, reduced capillary density, and tubulointerstitial fibrosis in human chronic kidney disease (6, 7) , and in a study of renal allograft rejection in the mouse in which macrophages were shown to promote peritubular capillary loss (29) . Our findings are also consistent with a study in which CC chemokine receptor 1 (CCR1) antagonism suppressed the development of renal fibrosis in the late phase of mouse lupus nephritis, although the precise contribution of macrophages in this fibrotic process is unclear as CCR1 antagonism reduced both T cell and macrophage infiltration (1) .
In marked contrast to the central role of macrophages in disruption of Bowman's capsule and glomerular crescent formation in the first 14 days of experimental NTN, macrophage depletion over days 14 to 35 had only minor effects on the number and size of glomerular crescents. Presumably, this represents the irreversible nature of fibrocellular crescents following disruption of Bowman's capsule (4) . The small reduction in crescent number seen on day 35 with high-dose fms-I treatment may reflect resolution of the small number of early cellular crescents present on day 14. The profibrotic role for macrophages in this model of chronic kidney disease is associated with a change from a classically activated proinflammatory M1 to an alternatively activated M2 phenotype from day 14 to 35. This shift in macrophage phenotype presumably reflects a change in the microenvironment within the injured kidney. However, it is not clear whether the M2-type macrophages seen on day 35 of disease represent a different activation pattern of newly recruited monocytes, or whether it indicates that M1-type macrophages present within the kidney on day 14 undergo phenotypic change-or a combination of both mechanisms may operate. Further studies are needed to delineate this issue.
In apparent contrast to our findings, recent studies have described an M1 to M2 change in macrophage phenotype during the resolution of tubulointerstitial damage following reversal of unilateral ureteric obstruction (19) . Macrophage depletion delays recovery of kidney structure and function after ischemiareperfusion injury indicating a reparative function for the M2-type macrophages in these lesions (21, 23) . However, other studies indicate that M2-type macrophages can exert a profibrotic role in kidney disease. M2-type macrophages expressing the CD163 and CD204 markers are seen in new-onset IgA nephropathy, where they are often located in areas of glomerular and interstitial fibrosis, and their numbers correlate with mesangial expansion and interstitial fibrosis (14) . Dexamethasone is a potent inducer of M2-type alternative macrophage activation and steroids are commonly used in the treatment of glomerulonephritis. In a study of rat Thy-1 mesangial proliferative nephritis, dexamethasone treatment induced M2-type alternative macrophage activation which augmented the incidence of global sclerosis and upregulated a number of profibrotic factors (13) .
It is clearly too simplistic to label alternatively activated M2-type macrophages as having only a reparative role in kidney disease (2) . For example, in our rat day 14-to-35 NTN study, there was ongoing severe kidney damage and the profibrotic role of macrophages in this context may still be one of attempting tissue repair, but simply failing to improve the outcome. A major difference between this NTN study and other models showing a reparative role for M2-type macrophages is that they are performed in models of transient tubular injury which allows examination of tubulointerstitial repair in the absence of ongoing renal injury. Thus, while "M2-type" macrophages are present in both situations, the very different renal microenvironment in a repairing kidney vs. one with persistent inflammatory damage means that although these M2-type macrophages may share upregulated expression of a number of specific genes, these populations are likely to have very different functional properties. Furthermore, depletion of the entire macrophage population in our model of established rat NTN means that while the overall effect of the macrophage infiltrate is profibrotic, there could be macrophage subsets with distinct pro-and anti-fibrotic actions within the overall infiltrate. An insight into this complex issue comes from adoptive transfer of ex vivo programmed M2-type macrophages that can suppress kidney injury in mouse adriamycin nephropathy despite the presence of endogenous macrophage populations (31, 32) .
In conclusion, this study established that macrophages contribute to renal dysfunction and tissue damage in established crescentic glomerulonephritis as it progresses from the acute inflammatory to a chronic fibrotic phase. These findings suggest that targeting macrophage recruitment and/or activation in the chronic fibrotic phase of disease may be beneficial. 
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